Hyaluronic acid may predict severity & prognosis of community-acquired pneumonia: Study
Hyaluronic acid (HA) has emerged as a promising biomarker for assessing the severity & prognosis of community-acquired pneumonia (CAP), showing strong diagnostic accuracy (AUC: 0.709) as published in the Journal of Inflammation Research.
Hyaluronic acid (HA) is a novel inflammatory biomarker with a prognostic value for several infectious diseases. This study investigated the association of Hyaluronic acid with severity and prognosis in hospitalized patients with community-acquired pneumonia (CAP). They analyzed the differences of Hyaluronic acid levels in different groups. Logistic regression analysis was performed to identify independent risk factors for severe CAP (SCAP). The predictive value of Hyaluronic acid for SCAP was assessed using receiver operating characteristic (ROC) curves. Kaplan-Meier survival analysis was used to compare 30-day mortality between the high and low Hyaluronic acid groups. Results: Compared to healthy controls (49.2 ± 15.3 ng/mL), patients with CAP exhibited significantly elevated levels of Hyaluronic acid(P < 0.001). In CAP patients, increased Hyaluronic acidlevels were more pronounced in those with SCAP (SCAP vs non-SCAP:135.6 ± 51 ng/mL vs 100.7 ± 47.8 ng/mL, P < 0.001). Compared to survivors (109.9 ± 48.7 ng/mL), Hyaluronic acid levels in non-survivors were significantly higher (180.9 ± 67.8 ng/mL) (P < 0.001). Hyaluronic acid was an independent predictor of SCAP [odds ratio (OR): 1.013, 95% confidence interval (CI): 1.003– 1.022, P = 0.011] with high diagnostic accuracy [areas under the curve (AUC): 0.709, 95% CI: 0.622– 0.797, P = 0.001]. Additionally, Hyaluronic acid was independently associated with death risk in patients with CAP (OR: 1.022, 95% CI: 1.005– 1.039, P = 0.010). Kaplan-Meier survival curves indicated that CAP patients in the high HA group exhibit a higher 30-day mortality rate compared to those in the low Hyaluronic acid group (8.6% vs 1.5%, P = 0.008). Post hoc analysis indicated that our study possessed 98.857% statistical power. In conclusion, High Hyaluronic acid levels are associated with severity and mortality in patients with CAP, and Hyaluronic acid could serve as a novel serum biomarker to predict the risk of CAP progression.
Reference:
Lin Y, Li Y, Cui X, Zhu N, Li X. Hyaluronic Acid is Associated with Severity and Prognosis in Patients with Community-Acquired Pneumonia. J Inflamm Res. 2024;17:11881-11895
https://doi.org/10.2147/JIR.S499326
Keywords:
Hyaluronic acid, predict, severity, prognosis, community-acquired pneumonia, study, Lin Y, Li Y, Cui X, Zhu N, Li X, Journal of Inflammation Research, hyaluronic acid, community-acquired pneumonia, severity, prognosis, biomarker
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.